Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto part. Organizers planned a second day of protests in May 2014, and in a statement released before the event said that millions of activists would join marches in over 400 cities in 52 countries on six continents. The day of protest took place on May 24. From 2009 to 2011, Monsanto improperly accounted for incentive rebates. The actions inflated Monsanto's reported profit by $31 million over the two years. Monsanto paid $80 million in penalties pursuant to a subsequent settlement with the US Securities and Exchange Commission. Monsanto materially misstated its consolidated earnings in response to losing market share of